lipogenesis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
== Awards == Archer Martin shared the 1952 Nobel Prize in Chemistry for the invention of partition chromatography with Richard Synge. Archer Martin's 1954 paper with Anthony T. James, "Gas-Liquid Chromatography: A Technique for the Analysis and Identification of Volatile Materials" reported the discovery of gas-liquid chromatography. This was performed at the National Institute for Medical Research in Mill Hill, London, which became the Francis Crick Institute in 2016. It was honoured by a Citation for Chemical Breakthrough Award from the Division of History of Chemistry of the American Chemical Society presented in 2016 to the Francis Crick Institute. Martin was elected a Fellow of the Royal Society in 1950, and made a CBE in 1960.
=== Abdominal migraine === Abdominal migraine is most frequently diagnosed in children, but occasionally in adults. Diagnostic criteria for abdominal migraine are outlined by both the Rome IV and ICHD III classification systems. Criteria include repeated, acute, paroxysmal attacks of abdominal pain that may be associated with nausea and vomiting. Attacks last for at least 1 hour and interfere with normal life. Average attack duration has been reported as 17 hours. Abdominal migraine often occurs in people with either a personal or family history of typical migraine, and children may develop typical migraine later in life. Abdominal migraine, migraine, and cyclical vomiting syndrome share common symptoms.
Peripheral blood smear Supportive blood work: mean cell volume (MCV), mean corpuscular hemoglobin concentration (MCHC), red blood cell distribution width (RDW), red blood cell count (RBC), reticulocytes, unconjugated bilirubin, haptoglobin, lactate dehydrogenase (LDH). Eosin-5-maleimide binding test Osmotic fragility test Acidified glycerol lysis test A negative direct antiglobin test (Coombs test)
== Neutron crystallography == Hydrogen–deuterium exchange of fast-exchanging species (e.g. hydroxyl groups) can be measured at atomic resolution quantitatively by neutron crystallography, and in real time if exchange is conducted during the diffraction experiment. High intensity neutron beams are generally generated by spallation at linac particle accelerators such as the Spallation Neutron Source. Neutrons diffract crystals similarly to X-rays and can be used for structural determination. Hydrogen atoms, with between one and zero electrons in a biological setting, diffract X-rays poorly and are effectively invisible under normal experimental conditions. Neutrons scatter from atomic nuclei, and are therefore capable of detecting hydrogen and deuterium atoms. Hydrogen atoms are routinely replaced with deuterium, which introduce a strong and positive scattering factor. It is often sufficient to replace only the solvent and labile hydrogen atoms in a protein crystal by vapor diffusion. In such a structure the occupancy of an exchangeable deuterium atom in a crystal will refine from 0-100%, directly quantifying the amount of exchange.
Sources: en.wikipedia.org
== Causes == In 2019, the epidemic was described by Rolling Stone as a "uniquely American problem". In 2017, prescription rates for opioids in the United States were 40 percent higher than the rate in other developed countries such as Germany or Canada. yet the FDA did not fully utilize its regulatory mechanisms to restrict the pharmaceutical industry.
Lipedema is a chronic medical condition that is almost exclusively found in women and results in enlargement of both legs due to deposits of fat under the skin. It is characterized by bilateral, symmetrical buildup of fat in the legs, and sometimes arms and lower trunk (includes hips, buttocks, and abdomen). Women of any weight may be affected and the fat is resistant to traditional weight-loss methods like nutritional intervention, exercise, elevation, diuretics or bariatric surgery. The feet/hands are typically spared, presenting with a raised ridge or fold of fat, possibly a "cuff" at the wrists and ankles. In earlier stages, there may be a subtle, raised ridge or fold of fat instead of distinct cuffing and sometimes in the later stages, this increased adipose above the ankle/wrist can cause the appearance of a "cuff". Approximately 50% of people with Lipedema report pain in their fat. Other common symptoms include swelling, feelings of heaviness, and easy bruising in the affected areas. Over time mobility may be reduced, and due to reduced quality of life, people often experience depression. The cause is unknown but is believed to involve genetic and hormonal factors, lipedema onset is typically associated with periods of hormonal flux like puberty, pregnancy, or menopause and it often runs in families. Other conditions that may present similarly include lipohypertrophy, chronic venous insufficiency, and lymphedema. It is commonly misdiagnosed.
== Kynurenine pathway dysfunction == Disorders affecting the kynurenine pathway may be primary (of genetic origin) or secondary (due to inflammatory conditions). Peripheral inflammation can lead to a build up of kynurenine in the brain, and this is associated with major depressive disorder, bipolar disorder, and schizophrenia. Dysfunction of the pathway not only causes increase in amounts of metabolites such as quinolinic acid and kynurenic acid but also affects synthesis of serotonin and melatonin. Kynurenine clearance in exercised muscle cells can suppress the build up in the brain.
Sources: en.wikipedia.org
=== Vaccines === When pseudouridine is used in place of uridine in synthetic mRNA, the modified mRNA molecule arouses less response from Toll-like receptors, a part of the human immune system that would otherwise identify the mRNA as unwelcome. This makes pseudouridine useful in mRNA vaccines, including the mRNA COVID-19 vaccines. This property of pseudouridine was discovered by Katalin Karikó and Drew Weissman in 2005, for which they shared the 2023 Nobel Prize in Physiology or Medicine. N1-Methylpseudouridine provides even less innate immune response than Ψ, as well as improving translation capacity. Both Pfizer-BioNTech and Moderna mRNA vaccines therefore use N1-Methylpseudouridine rather than Ψ.
{\displaystyle \int \limits _{\Omega }\rho {\frac {\partial \mathbf {u} }{\partial t}}\cdot \mathbf {v} -\int \limits _{\Omega }\mu \Delta \mathbf {u} \cdot \mathbf {v} +\int \limits _{\Omega }\rho (\mathbf {u} \cdot \nabla )\mathbf {u} \cdot \mathbf {v} +\int \limits _{\Omega }\nabla p\cdot \mathbf {v} =\int \limits _{\Omega }\mathbf {f} \cdot \mathbf {v} }
== Collaborations == Saladino describes himself as an "adventure buddy" of another carnivore diet influencer, Anthony Gustin, founder of online food store Perfect Keto. The pair visited the Hadza people of Tanzania in 2022, promoting them as a dietary model; Saladino said "The Hadza are the closest thing we have to a time machine." According to science writer Dorsa Amir, "the idea that the 'correct' diet is an ancient one is also the backbone of fads like the paleo diet, [and] Saladino's carnivore diet." Saladino is the founder of Heart & Soil, an Austin, Texas-based company producing food supplements. Saladino co-owns it with fellow carnivore diet influencer Brian Johnson, known as Liver King. Heart & Soil sells bottles of encapsulated organ meat-based supplement products and liver pills. He collaborated with California luxury grocery store Erewhon in 2023 on the store's Raw Animal-Based Smoothie, which mixes kefir (fermented milk), along with other ingredients, with beef organs and "Immunomilk" (a product made of freeze-dried cow's colostrum). The raw milk was supplied by California-based Raw Farms, until it switched to pasteurization after tests of its milk turned up positive for H5N1 influenza A virus. Consuming raw animal meat poses a risk of bacterial infection.
== Symptoms and signs == Abdominal obesity, often assessed using the waist-to-hip ratio, is associated with hyperinsulinemia. Direct measurement of serum insulin levels can identify elevated insulin, which may precede the onset of impaired glucose tolerance or hyperglycemia by 10 to 20 years. Consequently, normal fasting blood glucose levels alone do not rule out early-stage hyperinsulinemia. Some patients may experience a variety of symptoms when hypoglycemia is present, including:
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.